Billiontoone (NASDAQ:BLLN) Insider Sells $339,339.04 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 3,418 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $99.28, for a total value of $339,339.04. Following the completion of the transaction, the insider directly owned 32,482 shares in the company, valued at approximately $3,224,812.96. This trade represents a 9.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Tuesday, June 9th, Nancy Joann Johnson sold 10,582 shares of Billiontoone stock. The stock was sold at an average price of $100.47, for a total value of $1,063,173.54.

Billiontoone Price Performance

NASDAQ:BLLN traded down $3.13 during midday trading on Wednesday, hitting $99.26. The stock had a trading volume of 1,040,614 shares, compared to its average volume of 694,048. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The stock has a 50-day moving average of $87.26 and a 200 day moving average of $88.18. Billiontoone, Inc. has a one year low of $61.96 and a one year high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. The firm’s revenue was up 83.8% compared to the same quarter last year. During the same period last year, the business posted ($0.39) EPS. As a group, equities analysts predict that Billiontoone, Inc. will post 0.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BLLN. Weiss Ratings cut Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 5th. Guggenheim increased their target price on Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. BTIG Research dropped their target price on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. JPMorgan Chase & Co. increased their target price on Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $125.29.

Institutional Trading of Billiontoone

A number of institutional investors have recently made changes to their positions in BLLN. Adams Street Partners LLC acquired a new stake in shares of Billiontoone in the 4th quarter worth $140,063,000. Baillie Gifford & Co. acquired a new stake in shares of Billiontoone in the 4th quarter worth $103,786,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Billiontoone in the 4th quarter worth $39,717,000. JPMorgan Chase & Co. acquired a new stake in shares of Billiontoone in the 4th quarter worth $32,078,000. Finally, Wasatch Advisors LP acquired a new stake in shares of Billiontoone in the 1st quarter worth $29,179,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.